Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Iron overload could be a significant contributor to treatment-related mortality (TRM) for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). We studied 590 patients who underwent myeloablative allogeneic HSCT at our institution, and on whom a pretransplantation serum ferritin was available. An elevated pretransplantation serum ferritin level was strongly associated with lower overall and disease-free survival. Subgroup multivariable analyses demonstrated that this association was restricted to patients with acute leukemia or myelodysplastic syndrome (MDS); in the latter group, the inferior survival was attributable to a significant increase in TRM. There was also a trend toward an increased risk of veno-occlusive disease in patients with high ferritin. Our results argue that iron overload plays an important role in transplantation outcome for patients with acute leukemia or MDS, as it does in thalassemia. They also suggest future prospective trials to examine the potential benefit of chelation therapy in this setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ferritin levels (a common measure of body iron stores) are also widely associated with disease development/ severity/ poor outcomes (e.g. Alissa et al. 2007; Armand et al. 2007; Bartzokis et al. 2007; Braun et al. 2004; Bugianesi et al. 2004; Chen et al. 2006; Choi et al. 2005; Double et al. 2000; Fargion et al. 2001; Fernández-Real et al. 2002; Ford and Cogswell 1999; Forouhi et al. 2007; He et”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Survival in Medically Treated Patients with Homozygous β-Thalassemia
Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., & Cohen, A. R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409013310903 · Cited by 852
Bone Marrow Transplantation in Patients with Thalassemia
Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Politi, P., Durazzi, S. M. T., Muretto, P., & Albertini, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220701 · Cited by 636
Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major
Olivieri, N. F., Brittenham, G. M., McLaren, C. E., Templeton, D. M., Cameron, R. G., McClelland, R. A., Burt, A. D., & Fleming, K. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390701 · Cited by 420
Marrow Transplantation in Patients with Thalassemia Responsive to Iron Chelation Therapy
Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Andreani, M., Agostinelli, F., Albertini, F., & Clift, R. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309163291204 · Cited by 227
Marrow transplantation for patients with thalassemia: results in class 3 patients
Lucarelli, G., Clift, R., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Andreani, M., Manna, M., Nesci, S., et al. (1996) · Blood · doi:10.1182/blood.v87.5.2082.2082 · Cited by 216
Alyea, E. P., Kim, H. T., Ho, V., Cutler, C., DeAngelo, D. J., Stone, R., Ritz, J., Antin, J. H., & Soiffer, R. J. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.06.003 · Cited by 186
Self-citationMiceli, M. H., Dong, L., Grazziutti, M., Fassas, A., Thertulien, R., van Rhee, F., Barlogie, B., & Anaissie, E. J. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705340 · Cited by 128
Altés, A., Remacha, A. F., Sureda, A. M., Martino, R., Briones, J., Canals, C., Brunet, S., Sierra, J., & Gimferrer, E. (2002) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703570 · Cited by 121
Brittenham, G. M., Sheth, S., Allen, C. J., & Farrell, D. E. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90059-9 · Cited by 77
Cited by
Guidelines for the diagnosis and management of adult aplastic anaemia
Killick, S. B., Bown, N., Cavenagh, J., Dokal, I., Foukaneli, T., Hill, A., Hillmen, P., Ireland, R., Kulasekararaj, A., Mufti, G., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13853 · Cited by 749
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Knovich, M. A., Storey, J. A., Coffman, L. G., Torti, S. V., & Torti, F. M. (2009) · Blood Reviews · doi:10.1016/j.blre.2008.08.001 · Cited by 627
Bejar, R., Stevenson, K. E., Caughey, B., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G., Steensma, D. P., Ritz, J., Soiffer, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 396
Self-citationAdès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Metadata
- Authors
- Armand, P., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Soiffer, R. J., & Antin, J. H.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Department of Medical Oncology and
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-01-18
- Volume
- 109
- Issue
- 10
- Pages
- 4586-4588
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC1885508
- OpenAlex
- W268116559
- Cited by
- 426
- References
- 18
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 7 · 2021: 13 · 2020: 14 · 2019: 16 · 2018: 8 · 2017: 23 · 2016: 25 · 2015: 24 · 2014: 36 · 2013: 45 · 2012: 30
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL070149)
- National Cancer Institute (T32CA009172)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- serum ferritin, iron overload, allogeneic transplantation, non-relapse mortality, acute leukemia, myelodysplastic syndrome, veno-occlusive disease, overall survival, disease-free survival, iron chelation therapy, hematologic malignancies
- MeSH terms
- Albumins, Ferritins, Hepatic Veno-Occlusive Disease, Humans, Immunosuppression Therapy, Myelodysplastic Syndromes, Myeloproliferative Disorders, Prognosis, Recurrence, Retrospective Studies, Serologic Tests, Survival Analysis, Hematopoietic Stem Cell Transplantation, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. https://app.cochat.ai/papers/10.1182/blood-2006-10-054924
- The paper
- Armand, P., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Soiffer, R. J., & Antin, J. H. (2007). Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. https://doi.org/10.1182/blood-2006-10-054924
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.